SCHEMBL758231

SCHEMBL758231

C[Si](C)(C)CCOCn1cc2cc(Br)cc(-c3cc4ccccc4s3)c2n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3R1 P27986 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ APP P05067 2/20 0.33
▸ DGAT1 O75907 3/20 0.33
▸ MAPKAPK2 P49137 3/20 0.32
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ S1PR1 P21453 1/20 0.31
▸ PDE10A Q9Y233 1/20 0.30
▸ CD274 Q9NZQ7 1/20 0.30
▸ CDC7 O00311 1/20 0.30
▸ PLK4 O00444 1/20 0.30
▸ AURKA O14965 1/20 0.30
▸ MAPK13 O15264 1/20 0.30
▸ PDPK1 O15530 1/20 0.30
▸ DAPK3 O43293 1/20 0.30
▸ DYRK3 O43781 1/20 0.30
▸ ROCK2 O75116 1/20 0.30
▸ PRKD3 O94806 1/20 0.30
▸ MAP4K4 O95819 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761006 0.83 MAPKAPK2 (0.43) APPMAPKAPK2CDC7PLK4AURKA
SCHEMBL760853 0.83 PDGFRB (0.37) KDR
SCHEMBL761248 0.81 DGAT1 (0.35) PIK3R1PIK3CAAPPDGAT1MAPKAPK2
SCHEMBL760831 0.78 DGAT1 (0.34) PIK3R1PIK3CAAPPDGAT1MAPKAPK2
SCHEMBL2426862 0.75 DGAT1 (0.37) DGAT1
SCHEMBL25200103 0.74 DGAT1 (0.43) DGAT1
SCHEMBL2423774 0.73 DGAT1 (0.34) DGAT1
SCHEMBL24163679 0.72 DGAT1 (0.36) DGAT1PDE10A
SCHEMBL29192464 0.71 DGAT1 (0.37) DGAT1PDE10A
SCHEMBL1771115 0.69 DGAT1 (0.42) DGAT1HDAC6S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 — — US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 — — US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 — — US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 — — US disclosed
EP-2001480-A2 INDAZOLE COMPOUNDS Abbott Laboratories (US) 2008-12-17 — — EP disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 PIK3R1 1014/4885PIK3CA 979/4885APP 3504/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 PIK3R1 1014/4885PIK3CA 979/4885APP 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback